Published in Pharma Law Weekly, August 22nd, 2006
The quarter was marked by a 45% increase in sales of Biosite's non-BNP cardiovascular products, compared with the same quarter of 2005, and by continued market leadership of the Triage BNP Test, which is primarily used to aid in the diagnosis of heart failure. The company also announced that it has resolved all outstanding patent litigation with Roche Diagnostics and several of its affiliates.
Under the terms of a settlement agreement announced, Biosite and Roche have each agreed to file appropriate requests to dismiss their respective complaints pending in Federal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly